Wedbush reiterated their outperform rating on shares of Epizyme Inc. (NASDAQ:EPZM) in a research report sent to investors on Monday. They currently have a $22.00 price target on the biopharmaceutical company’s stock.

A number of other research analysts have also recently commented on EPZM. HC Wainwright reiterated a buy rating on shares of Epizyme in a research report on Tuesday, August 9th. Zacks Investment Research upgraded shares of Epizyme from a sell rating to a hold rating in a research report on Wednesday, August 10th. Leerink Swann reiterated an outperform rating on shares of Epizyme in a research report on Friday, October 7th. Finally, JMP Securities reiterated a buy rating on shares of Epizyme in a research report on Sunday, November 6th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Epizyme has a consensus rating of Buy and an average target price of $23.11.

Epizyme (NASDAQ:EPZM) opened at 11.30 on Monday. The company’s 50 day moving average is $9.94 and its 200-day moving average is $9.79. The firm’s market cap is $655.52 million. Epizyme has a 52-week low of $7.02 and a 52-week high of $18.29.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.18. Epizyme had a negative net margin of 1,205.01% and a negative return on equity of 41.56%. The business had revenue of $6.60 million for the quarter. On average, equities analysts predict that Epizyme will post ($1.98) EPS for the current fiscal year.

WARNING: “Epizyme Inc. (EPZM) Receives “Outperform” Rating from Wedbush” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of US and international trademark & copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2016/11/29/epizyme-inc-epzm-receives-outperform-rating-from-wedbush.html.

A number of institutional investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd purchased a new position in shares of Epizyme during the second quarter valued at approximately $104,000. BlackRock Group LTD increased its position in shares of Epizyme by 3.7% in the third quarter. BlackRock Group LTD now owns 10,374 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 371 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Epizyme by 15.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,347 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,102 shares during the last quarter. BlackRock Advisors LLC increased its position in shares of Epizyme by 12.5% in the third quarter. BlackRock Advisors LLC now owns 21,244 shares of the biopharmaceutical company’s stock valued at $209,000 after buying an additional 2,365 shares during the last quarter. Finally, American International Group Inc. increased its position in shares of Epizyme by 36.2% in the second quarter. American International Group Inc. now owns 23,167 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 6,155 shares during the last quarter. 79.69% of the stock is owned by institutional investors and hedge funds.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

5 Day Chart for NASDAQ:EPZM

Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.